For this reason, research groups are working to improve the performance of this therapeutic strategy, targeting genes encoding immune checkpoint proteins, e.g., PD1 [96,97], or suppressing IL-2 [97,98] in mouse cancer models. The gene discussed is IL2; the disease is cancer.